Fennec Pharmaceuticals Inc.

NasdaqCM FENC

Fennec Pharmaceuticals Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -131.44

Fennec Pharmaceuticals Inc. Price to Earnings Ratio (P/E) is -131.44 on January 14, 2025, a -753.13% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Fennec Pharmaceuticals Inc. 52-week high Price to Earnings Ratio (P/E) is 106.70 on April 02, 2024, which is 181.18% above the current Price to Earnings Ratio (P/E).
Fennec Pharmaceuticals Inc. 52-week low Price to Earnings Ratio (P/E) is -144.90 on December 26, 2024, which is -10.24% below the current Price to Earnings Ratio (P/E).
Fennec Pharmaceuticals Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -1.96.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: FENC

Fennec Pharmaceuticals Inc.

CEO	Mr. Rostislav Raykov
IPO Date	Sept. 15, 2017
Location	United States
Headquarters	68 TW Alexander Drive
Employees	29
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Key trends

Past 5 years